Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Statistical consideration for clinical biomarker research in bladder cancer

(2010) Shahrokh F. Shariat et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Considerations on implementing diagnostic markers into clinical decision making in bladder cancer

(2010) Yair Lotan et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection

(2009) Yair Lotan et al.   BJU INTERNATIONAL

Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumor Marker

(2009) Yair Lotan et al.   JOURNAL OF UROLOGY

Decision Analysis for the Evaluation of Diagnostic Tests, Prediction Models, and Molecular Markers

(2008) Andrew J Vickers   AMERICAN STATISTICIAN

Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma

(2008) Georg C. Hutterer et al.   BJU INTERNATIONAL

Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection

(2008) Yair Lotan et al.   BJU INTERNATIONAL